Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

Researchers uncover promising evidence that xenon gas, commonly used in anesthesia, may help reduce brain deterioration and ...

A common cognitive disorder with symptoms that mimic Alzheimer's is often mistaken for the disease. Researchers are calling for criteria to diagnose the little-known condition.

Access to the new Alzheimer's drugs is limited by strict eligibility criteria, long wait times, and a lack of infusion centers.

Amneal Pharmaceuticals has received approval from the Food and Drug Administration for a dementia treatment and a drug targeting certain types of brain tumors, as well as tentative approval for a drug ...

New guidelines will help doctors identify patients with a common memory-loss syndrome that is often misdiagnosed as Alzheimer's disease in older adults. The diagnostic criteria for limbic-predominant ...

Xenon gas, currently used in medicine as an anesthetic and neuroprotective agent for treating brain injuries, showed potential in protecting the brain in studies.

Vigil Neuroscience reported a strong safety profile and 50% sTREM2 reduction in an early-stage trial for VG-3927, potentially representing a new avenue for treating Alzheimer’s disease.

Aerobic exercise significantly lowers Alzheimer’s disease markers and improves brain health, offering a promising preventive ...

Vigil posted positive phase 1 results for VG-3927, but competitor Alector's failure raises concerns about phase 2. Click here ...

A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...